NASDAQ:TMCI Treace Medical Concepts (TMCI) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free TMCI Stock Alerts $11.04 -0.23 (-2.04%) (As of 01:52 PM ET) Add Compare Share Share Today's Range$10.82▼$11.5150-Day Range$11.27▼$15.8652-Week Range$5.27▼$27.70Volume189,068 shsAverage Volume479,269 shsMarket Capitalization$681.83 millionP/E RatioN/ADividend YieldN/APrice Target$19.58 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Treace Medical Concepts alerts: Email Address Treace Medical Concepts MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside71.2% Upside$19.58 Price TargetShort InterestHealthy6.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.91) to ($0.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.60 out of 5 starsMedical Sector441st out of 918 stocksSurgical & Medical Instruments Industry49th out of 97 stocks 3.4 Analyst's Opinion Consensus RatingTreace Medical Concepts has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTreace Medical Concepts has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.11% of the float of Treace Medical Concepts has been sold short.Short Interest Ratio / Days to CoverTreace Medical Concepts has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Treace Medical Concepts has recently decreased by 9.90%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTreace Medical Concepts does not currently pay a dividend.Dividend GrowthTreace Medical Concepts does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TMCI. Previous Next 2.0 News and Social Media Coverage News SentimentTreace Medical Concepts has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Treace Medical Concepts this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for TMCI on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Treace Medical Concepts insiders have not sold or bought any company stock.Percentage Held by Insiders24.43% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.08% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Treace Medical Concepts are expected to grow in the coming year, from ($0.91) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Treace Medical Concepts is -14.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Treace Medical Concepts is -14.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTreace Medical Concepts has a P/B Ratio of 5.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Treace Medical Concepts Stock (NASDAQ:TMCI)Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.Read More TMCI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TMCI Stock News HeadlinesApril 17, 2024 | finance.yahoo.comTreace to Present at Bank of America Health Care ConferenceApril 16, 2024 | globenewswire.comTreace Announces First Annual National Bunion DayApril 19, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 15, 2024 | investorplace.com7 Stable Stocks for 50% Returns by Early 2025April 14, 2024 | americanbankingnews.comTreace Medical Concepts (NASDAQ:TMCI) Stock Price Down 5.2%April 9, 2024 | globenewswire.comTreace to Report First Quarter 2024 Financial ResultsMarch 25, 2024 | globenewswire.comTreace Celebrates 100,000 Lapiplasty® 3D Bunion Correction® Patient MilestoneMarch 1, 2024 | seekingalpha.comTreace Medical Concepts Inc (TMCI) Q4 2023 Earnings Call TranscriptApril 19, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 1, 2024 | finance.yahoo.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Just Reported And Analysts Have Been Lifting Their Price TargetsMarch 1, 2024 | morningstar.comTreace Medical Concepts IncFebruary 29, 2024 | finance.yahoo.comTreace Medical Concepts Full Year 2023 Earnings: EPS Misses ExpectationsFebruary 29, 2024 | finance.yahoo.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | markets.businessinsider.comBuy Rating on Treace Medical Concepts: Promising Financial Outlook and Strategic Product Innovation Drive GrowthFebruary 27, 2024 | finance.yahoo.comTreace Medical Concepts Inc (TMCI) Reports Robust Revenue Growth and Expands Surgeon Base in Q4 ...February 27, 2024 | globenewswire.comTreace Medical Concepts Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 GuidanceFebruary 20, 2024 | msn.comGlobus Medical (GMED) Q4 Earnings and Revenues Beat EstimatesFebruary 20, 2024 | finance.yahoo.comEarnings Preview: Treace Medical Concepts (TMCI) Q4 Earnings Expected to DeclineFebruary 20, 2024 | finance.yahoo.comTMCI Sep 2024 20.000 callFebruary 20, 2024 | finance.yahoo.comTMCI Jun 2024 22.500 callFebruary 18, 2024 | finance.yahoo.comTMCI Mar 2024 17.500 callFebruary 17, 2024 | finance.yahoo.comTMCI Mar 2024 25.000 callFebruary 13, 2024 | uk.investing.comTreace Medical Concepts Inc (TMCI)February 7, 2024 | finance.yahoo.comTreace to Report Fourth Quarter and Full-Year 2023 Financial ResultsFebruary 2, 2024 | finance.yahoo.comTreace Announces Interim 3-Year ALIGN3D™ Clinical Study Data at the 2024 ACFAS Scientific Conference Demonstrating Sustained, Positive Outcomes of the Lapiplasty® ProcedureFebruary 1, 2024 | finance.yahoo.comTreace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific ConferenceJanuary 31, 2024 | markets.businessinsider.comTruist Financial Sticks to Their Buy Rating for Treace Medical Concepts (TMCI)See More Headlines Receive TMCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/19/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:TMCI CUSIPN/A CIK1630627 Webwww.treace.com Phone904-373-5940FaxN/AEmployees516Year FoundedN/APrice Target and Rating Average Stock Price Target$19.58 High Stock Price Target$27.50 Low Stock Price Target$11.00 Potential Upside/Downside+73.8%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,530,000.00 Net Margins-26.47% Pretax Margin-26.47% Return on Equity-33.96% Return on Assets-19.99% Debt Debt-to-Equity Ratio0.38 Current Ratio4.40 Quick Ratio3.76 Sales & Book Value Annual Sales$187.12 million Price / Sales3.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book5.03Miscellaneous Outstanding Shares61,760,000Free Float46,668,000Market Cap$696.04 million OptionableOptionable Beta0.27 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. John T. Treace (Age 52)CEO, Founder & Director Comp: $1.09MMr. Mark L. Hair CPA (Age 54)Chief Financial Officer Comp: $599.7kMr. Aaron J. Berutti (Age 45)Senior Vice President of Sales Comp: $484.22kMr. Terry W. Lubben (Age 59)Senior Vice President of Operations Ms. Julie D. Dewey (Age 63)Chief Communications & Investor Relations Officer Mr. Scot M. Elder J.D. (Age 49)Chief Legal & Compliance Officer and Corporate Secretary Mr. Nathan MinnichSenior Vice President of MarketingMr. Daniel E. Owens (Age 52)Chief Human Resources Officer Dr. Sean F. Scanlan Ph.D. (Age 42)Chief Innovation Officer Ms. Shana ZinkSenior Vice President of Clinical Affairs, Medical Education & ReimbursementMore ExecutivesKey CompetitorsOrthoPediatricsNASDAQ:KIDSAtrionNASDAQ:ATRISilk Road MedicalNASDAQ:SILKSI-BONENASDAQ:SIBNParagon 28NYSE:FNAView All CompetitorsInsiders & InstitutionsWealth Enhancement Advisory Services LLCSold 9,000 shares on 4/16/2024Ownership: 0.390%Newbridge Financial Services Group Inc.Bought 3,567 shares on 3/28/2024Ownership: 0.012%Vanguard Group Inc.Bought 104,207 shares on 3/11/2024Ownership: 6.952%Perceptive Advisors LLCSold 583,655 shares on 2/26/2024Ownership: 2.027%Price T Rowe Associates Inc. MDBought 1,107 shares on 2/16/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions TMCI Stock Analysis - Frequently Asked Questions Should I buy or sell Treace Medical Concepts stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TMCI shares. View TMCI analyst ratings or view top-rated stocks. What is Treace Medical Concepts' stock price target for 2024? 6 analysts have issued 12 month price targets for Treace Medical Concepts' shares. Their TMCI share price targets range from $11.00 to $27.50. On average, they expect the company's share price to reach $19.58 in the next year. This suggests a possible upside of 71.2% from the stock's current price. View analysts price targets for TMCI or view top-rated stocks among Wall Street analysts. How have TMCI shares performed in 2024? Treace Medical Concepts' stock was trading at $12.75 at the beginning of the year. Since then, TMCI stock has decreased by 10.3% and is now trading at $11.44. View the best growth stocks for 2024 here. When is Treace Medical Concepts' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our TMCI earnings forecast. How can I listen to Treace Medical Concepts' earnings call? Treace Medical Concepts will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Treace Medical Concepts' earnings last quarter? Treace Medical Concepts, Inc. (NASDAQ:TMCI) announced its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.01. The company earned $62.20 million during the quarter, compared to analysts' expectations of $60.56 million. Treace Medical Concepts had a negative trailing twelve-month return on equity of 33.96% and a negative net margin of 26.47%. Treace Medical Concepts's revenue for the quarter was up 24.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.08) EPS. What guidance has Treace Medical Concepts issued on next quarter's earnings? Treace Medical Concepts updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $220.0 million-$225.0 million, compared to the consensus revenue estimate of $223.2 million. When did Treace Medical Concepts IPO? Treace Medical Concepts (TMCI) raised $150 million in an IPO on Friday, April 23rd 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and SVB Leerink and Stifel were co-managers. Who are Treace Medical Concepts' major shareholders? Treace Medical Concepts' stock is owned by many different institutional and retail investors. Top institutional investors include Wealth Enhancement Advisory Services LLC (0.39%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, F Barry Bays, Jaime A Frias, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie. View institutional ownership trends. How do I buy shares of Treace Medical Concepts? Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TMCI) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIThe #1 Crypto for 2024InvestorPlaceHe Is Giving Away BitcoinCrypto Swap Profits1970’s computer coder issues shocking A.I. warningTradeSmithSHOCKING Crypto Leak…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Treace Medical Concepts, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.